A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

IRB/UVA Tracking #
20984
Contact
Linsey Jackson
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Paul Kunk
Status
OPEN TO ACCRUAL